Harbour BioMed Signs Strategic Collaboration Agreement With Vir Biotechnology To Develop Novel Therapies For Immuno-Oncology And Infectious Diseases
Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company announced that it has entered into a strategic collaboration with Vir Biotechnology (Nasdaq: VIR), a clinical-stage immunology company, to discover, develop and commercialize potential novel therapeutic molecules in the fields of Immuno-Oncology and infectious diseases.
HBM will leverage its tools in next-generation technologies including its transgenic Harbour Mice® platforms to generate antibodies for the collaboration. Both parties will then combine their expertise in basic science to accelerate the development of these innovative immunotherapies into the clinic studies for patients suffering from cancers and infectious diseases.
"We are excited to join hands with Vir as both companies share a common mission to serve patients' unmet needs," said Dr. Jingsong Wang, the Founder, Chairman, and CEO of Harbour BioMed. "This collaborative partnership harbors big potential for both companies, as we exploit similar underlying immune mechanisms that likely play a critical role in fighting cancers as well as infectious diseases."